This paper demonstrates rapid technology transfer of an external CHO cell line (Sartorius 4Cell SmartCHO) into FUJIFILM Biotechnologies’ standardized mAb platform. Side-by-side runs (Ambr 250) and scale-up to 10 L showed comparable growth, metabolites, titer, and CQAs, enabling robust performance without extensive custom optimization. The approach is scalable toward pilot (200 L) and, supported by FUJIFILM Biotechnologies’ global network, offers a standardized yet flexible path that accelerates development and reduces risk from CLD through cGMP manufacturing.

This paper demonstrates rapid technology transfer of an external CHO cell line (Sartorius 4Cell SmartCHO) into FUJIFILM Biotechnologies’ standardized mAb platform. Side-by-side runs (Ambr 250) and scale-up to 10 L showed comparable growth, metabolites, titer, and CQAs, enabling robust performance without extensive custom optimization. The approach is scalable toward pilot (200 L) and, supported by FUJIFILM Biotechnologies’ global network, offers a standardized yet flexible path that accelerates development and reduces risk from CLD through cGMP manufacturing. Fill out the form on this page to discover more.

Primary Interest(Required)
This field is hidden when viewing the form
Segments(Required)
This field is hidden when viewing the form
Sub-Segments(Required)
Privacy Policy(Required)
By submitting this form I agree that FUJIFILM Biotechnologies may process my data in the manner described in FUJIFILM’s Privacy Policy